Long-term functional alterations following prenatal GLP-1R activation
Devon L Graham1, Haley S Madkour1, Brenda L Noble1
1Department of Biomedical Sciences and Center for Brain Repair, Florida State University College of Medicine, Tallahassee, FL 32306, United States of America.
Neurotoxicology and Teratology
|April 17, 2021
Summary
Glucagon-like peptide-1 receptor (GLP-1R) activation during pregnancy minimally impacted mothers but altered offspring weight and anxiety-like behaviors. This suggests a sex-specific developmental role for GLP-1R in stress response.
Area of Science:
- Pharmacology
- Neuroscience
- Developmental Biology
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists are increasingly used for conditions beyond type 2 diabetes and obesity.
- The impact of GLP-1R activation during pregnancy on maternal and offspring health remains largely unknown.
Purpose of the Study:
- To investigate the effects of GLP-1R activation during pregnancy on maternal and offspring outcomes.
- To explore potential developmental roles of GLP-1R modulation in offspring behavior and physiology.
Main Methods:
- Female C57Bl/6J mice were treated with the GLP-1R agonist Exendin-4 prior to and throughout gestation.
- Maternal care, offspring weight, and behavioral domains (reward, depression, activity, cognition, anxiety) were assessed.
Main Results:
- Exendin-4 treatment had minimal effects on dams, potentially enhancing maternal care.
- Offspring exposed to Exendin-4 showed increased preweaning weight and altered anxiety-like behaviors.
- Few significant changes were observed in offspring reward, depression, activity, or cognition.
Conclusions:
- Pregnancy GLP-1R activation may have a developmental role in the maternal stress response, potentially sex-specific.
- Further research is needed to understand the long-term implications of prenatal GLP-1R exposure.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
530
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
530
01:20Pathophysiology of Diabetes
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.3K
01:09GPCRs Regulate Adenylyl Cylase Activity
6.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.3K